Blue­bird bio or­ches­trates a se­ries of deals and a buy­out to guar­an­tee gene ther­a­py man­u­fac­tur­ing

A day af­ter The New York Times spot­light­ed the man­u­fac­tur­ing and sup­ply prob­lems be­set­ting a boom­ing gene ther­a­py field, with key play­ers scram­bling to main­tain a stock of the be­nign virus­es need­ed to make their prod­ucts, blue­bird bio $BLUE has come up with what it sees as a de­fin­i­tive so­lu­tion to the prob­lem.

The late-stage biotech has snagged a par­tial­ly com­plete man­u­fac­tur­ing com­plex in Durham, NC to do its own in-house man­u­fac­tur­ing work while ex­e­cut­ing a se­ries of con­tracts with sup­pli­ers. And blue­bird ex­ecs say the bas­ket of deals places them in con­trol of their own des­tiny — at least as far as man­u­fac­tur­ing is con­cerned.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER